Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

The problem is that these Glucagon-like peptide-1 (GLP-1 ... on their use in these patients,” senior researcher Dr. Jung-Im Shin, an associate professor at Johns Hopkins Bloomberg School ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, despite limited data on the drugs’ safety and effectiveness in this patient ...

One of the peptide products is glucagon-like peptide 1 ... metabolism and eating patterns than mice do), they found that an intramuscular injection of BRP prior to feeding reduced food intake ...

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, ...

One of the peptide products is glucagon-like peptide 1 ... they found that an intramuscular injection of BRP prior to feeding reduced food intake over the next hour by up to 50% in both animal ...